UK government to consult on value-based pricing in December
This article was originally published in Scrip
Executive Summary
Pharmaceutical companies operating in the UK may soon have a clearer idea of the shape of the new value based pricing (VBP) system for setting the price of drugs. The Department of Health will launch a consultation on proposals for VBP next month, according to the department's Business Plan 2011-2015. The government expects the new system to be up and running in January 2014, ready to replace the current Pharmaceutical Price Regulation Scheme when it comes to an end. The department will actually begin developing the system, together with pharmaceutical companies, next April. Value-based pricing forms part of the UK coalition government's plans to overhaul the National Health System to create a "patient-led NHS" and to improve healthcare outcomes.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.